Scipher Medicine, a Waltham, MA-based precision immunology company, raised $110M in funding.
The round was led by Cowen Healthcare Investments, with participation from Neuberger Berman, Hitachi Ventures, Laurion Capital, Monashee Investment Management, Northpond Ventures, aMoon, Khosla Ventures, Optum Ventures, Echo Health Ventures, and Alumni Ventures. Tim Anderson, partner and head of Research at Cowen Healthcare Investments, is joining Scipher’s Board of Directors.
The company, which has raised $227m, intends to use the funds to expand its development efforts and business reach.
Led by Alif Saleh, chief executive officer, Scipher is a precision immunology company matching patients with their most effective therapy. Using Spectra™, its proprietary network medicine platform, the company commercializes tests revealing a person’s unique molecular disease signature and match it to the most effective therapy, ensuring optimal treatment from day one. The patient molecular data generated from the tests further supports the discovery and development of novel and more effective therapeutics. Scipher partners with leading payers, health care providers, and pharmaceutical companies to bring solutions to patients with autoimmune diseases.